Article Versions Notes

Gartrell J, Navid F, Yuan X, Ness KK, Dubrovin M, Wang F, Pan H, McCarville MB, Shulkin BL, Helmig S, et al. ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing Sarcoma. Cancers. 2025; 17(17):2894. https://doi.org/10.3390/cancers17172894

Gartrell, Jessica, Fariba Navid, Xiaomeng Yuan, Kirsten K. Ness, Mikhail Dubrovin, Fang Wang, Haitao Pan, Mary Beth McCarville, Barry L. Shulkin, Sara Helmig, and et al. 2025. "ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing Sarcoma" Cancers 17, no. 17: 2894. https://doi.org/10.3390/cancers17172894

Gartrell, J., Navid, F., Yuan, X., Ness, K. K., Dubrovin, M., Wang, F., Pan, H., McCarville, M. B., Shulkin, B. L., Helmig, S., Krasin, M. J., Neel, M. D., Davidoff, A. M., Mandrell, B. N., Levine, D. R., Cai, Z., Bishop, M. W., Pappo, A. S., & Federico, S. M. (2025). ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing Sarcoma. Cancers, 17(17), 2894. https://doi.org/10.3390/cancers17172894